...
首页> 外文期刊>Materials science & engineering >Intraperitoneal transplantation of bioengineered humanized liver grafts supports failing liver in acute condition
【24h】

Intraperitoneal transplantation of bioengineered humanized liver grafts supports failing liver in acute condition

机译:生物工程人源化肝移植的腹膜内移植可支持急性状态下的衰竭肝

获取原文
获取原文并翻译 | 示例

摘要

Acute liver failure (ALF) is one of the most devastating fatal conditions which have posed crucial challenges to the clinicians and researchers for identifying permanent cure. Currently liver transplantation has been considered as the only managerial option. However it's wider applicability has been limited owing to non-availability of quality donor organs, cost-intensiveness, surgical hitches, life-long use of immunosuppressive drugs and long-term complications. Since last decades, several liver support systems have been developed for the management of failing liver in acute condition. However, the major limitation has been the lack of natural biological support and long-term survival of the grafts post-transplantation. Repopulation of decellularized xenogeneic organs is one of the emerging technologies for development of humanized neo-organs for demanding regenerative application. However, the earlier reported studies do not fulfil the insistence to provide immunologically tolerable humanized liver grafts for clinical applications. Here we demonstrate an efficient approach to generate transplantable humanized liver grafts which provides long-term support to the failing liver in Acute Liver Failure (ALF) animal models. These bioengineered humanized liver tissue grafts expresses several liver specific transcripts and performed crucial synthetic (albumin production) and detoxification (urea synthesis) functions at comparative level to normal liver. Intraperitoneal transplantation of these humanized liver grafts offered favourable microenvironment to exchange toxic substances across the barrier during ALF condition and provided long-term survival and function of the graft. In summary, the results of present study provide a first proof of concept in pre-clinical ALF animal model for the applicability of these bioengineered humanized livers in the management of failing liver on demand and may be considered as potential bridge to liver transplantation.
机译:急性肝衰竭(ALF)是最致命的致命疾病之一,对临床医生和研究人员确定永久治愈提出了严峻挑战。目前,肝移植被认为是唯一的管理选择。然而,由于无法获得优质的供体器官,成本密集,外科手术栓塞,终身使用免疫抑制剂和长期并发症等原因,其广泛的应用受到了限制。自从过去的几十年以来,已经开发了几种肝脏支持系统来管理急性状态下的衰竭肝。然而,主要的局限性是缺乏自然的生物支持和移植后移植物的长期存活。脱细胞异种器官的再填充是用于人性化新器官的发展的新兴技术之一,用于要求再生应用的人。然而,较早报道的研究不能满足为临床应用提供免疫耐受的人源化肝移植的要求。在这里,我们演示了一种生成可移植的人源化肝移植的有效方法,该方法可为急性肝衰竭(ALF)动物模型中的衰竭肝提供长期支持。这些生物工程化的人源化肝组织移植物表达了几种肝脏特异性转录本,并以与正常肝脏相当的水平执行了关键的合成(白蛋白产生)和解毒(尿素合成)功能。这些人源化肝移植的腹膜移植提供了有利的微环境,可以在ALF条件下通过屏障交换有毒物质,并提供了长期存活和功能。总而言之,本研究的结果为这些生物工程化人源化肝脏在按需衰竭肝的管理中的适用性提供了临床前ALF动物模型的第一个概念证明,并可能被视为通往肝移植的潜在桥梁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号